For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.
GH Secretagogue
Hexarelin
Research onlyWADA prohibited
Potent GH secretagogue with longer-lasting effect than GHRP-6; receptor desensitization can occur with chronic high doses.
At a glance
- Common vial size
- 5 mg
- Reference dose
- 100 mcg
- Frequency
- 1–2× daily
Reference titration protocol
100 mcg, 1–2× daily; cycle to avoid desensitization.
| Step | Dose | Duration | Administrations / week |
|---|---|---|---|
| 1 | 100 mcg | 4 weeks | 14× |
Reconstitution example
A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.
Open this configuration in the calculatorClinical notes
- Tachyphylaxis reported with continuous high-dose use — cycle dosing
Available formulations
Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.
- Lyophilized PowderR&D
Pricing and ordering are for verified accounts
VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.
Also in GH Secretagogue
Sermorelin
GHRH 1-29 analog that stimulates pulsatile endogenous GH release. Historically FDA-approved (Geref, withdrawn 2008); now compounded.
Tesamorelin
Stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Often compounded with ipamorelin in anti-aging protocols.
Ipamorelin
Selective ghrelin/GHS-R agonist that triggers pulsatile GH release with minimal cortisol or prolactin impact. WADA-prohibited.
CJC-1295 (no DAC)
GHRH analog often stacked with ipamorelin to amplify endogenous GH pulses. WADA-prohibited.
GHRP-2
Synthetic hexapeptide ghrelin-receptor agonist. Stronger GH release than GHRP-6 with less appetite stimulation.
GHRP-6
Ghrelin-receptor agonist with marked appetite-stimulant effect. Often stacked with a GHRH (sermorelin or CJC-1295).
